On September 10, 2021, multi-disciplinary research leaders will come together in New York City at the National Psoriasis Foundation (NPF) Research Symposium to present on the latest in psoriasis, psoriatic arthritis (PsA), and comorbidities research and how we can accelerate these efforts to improve patient quality of life.
Psoriasis is one of the most common immune-mediated diseases affecting US adults.  It is associated with underlying systemic inflammatory processes that can have wide-ranging effects on a person, including the development, or manifestation, of comorbidities such as PsA, cardiovascular disease, metabolic syndrome, and mental illness.
The Research Symposium, which is held every 2 years, will focus on improving health outcomes for individuals with psoriatic disease. Chaired by Iannis Adamopoulos, Ph.D., and Joseph Merola, M.D., the multi-disciplinary presentations this year will discuss health disparities, the value of using real world data, the growing body of research into the comorbidities of psoriatic disease, as well as the systemic effects of this chronic immune-mediated disease and other inflammatory diseases, among other topics.
Keynote and Plenary Sessions
Michelle McMurry-Heath, M.D., Ph.D., President and CEO of Biotechnology Innovation Organization (BIO) will provide the keynote address, where she will highlight the BIOEquality agenda as well as some of the outcomes from the recent BIO Clinical Trial Diversity Summit. Additionally, she will share how biotech is working toward breakthroughs for people with psoriasis and the types of research that are necessary to achieve those breakthroughs.
Joining Dr. McMurry-Heath on the main stage is 2021 Beverly Foster Plenary Lecture presenter, Mariana J. Kaplan, M.D., Chief of the Systemic Autoimmunity Branch at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Recently, her research has focused on identifying abnormalities of neutrophil subsets and the role of neutrophil extracellular traps in systemic autoimmune and immune-mediated disorders, both of which may contribute to the development of chronic inflammatory responses.